| 3E03002 | Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach |
| 3E03003 | Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach |
| 3E03005 | Introduction of Other Antineoplastic into Peripheral Vein, Open Approach |
| 3E0300M | Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach |
| 3E0300P | Introduction of Clofarabine into Peripheral Vein, Open Approach |
| 3E03016 | Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Open |
| 3E03017 | Introduction of Other Thrombolytic into Peripheral Vein, Open Approach |
| 3E03028 | Introduction of Oxazolidinones into Peripheral Vein, Open Approach |
| 3E03029 | Introduction of Other Anti-infective into Peripheral Vein, Open Approach |
| 3E0303Z | Introduction of Anti-inflammatory into Peripheral Vein, Open Approach |
| 3E0304Z | Introduction of Serum, Toxoid and Vaccine into Peripheral Vein, Open Approach |
| 3E0306Z | Introduction of Nutritional Substance into Peripheral Vein, Open Approach |
| 3E0307Z | Introduction of Electrolytic and Water Balance Substance into Peripheral Vein, Open Approach |
| 3E030FZ | Introduction of Intracirculatory Anesthetic into Peripheral Vein, Open Approach |
| 3E030GC | Introduction of Other Therapeutic Substance into Peripheral Vein, Open Approach |
| 3E030GN | Introduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Open Approach |
| 3E030HZ | Introduction of Radioactive Substance into Peripheral Vein, Open Approach |
| 3E030KZ | Introduction of Other Diagnostic Substance into Peripheral Vein, Open Approach |
| 3E030NZ | Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Open Approach |
| 3E030PZ | Introduction of Platelet Inhibitor into Peripheral Vein, Open Approach |
| 3E030RZ | Introduction of Antiarrhythmic into Peripheral Vein, Open Approach |
| 3E030TZ | Introduction of Destructive Agent into Peripheral Vein, Open Approach |
| 3E030U1 | Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Open Approach |
| 3E030VG | Introduction of Insulin into Peripheral Vein, Open Approach |
| 3E030VH | Introduction of Human B-type Natriuretic Peptide into Peripheral Vein, Open Approach |
| 3E030VJ | Introduction of Other Hormone into Peripheral Vein, Open Approach |
| 3E030WK | Introduction of Immunostimulator into Peripheral Vein, Open |
| 3E030WL | Introduction of Immunosuppressive into Peripheral Vein, Open |
| 3E030XZ | Introduction of Vasopressor into Peripheral Vein, Open Approach |
| 3E03302 | Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach |
| 3E03303 | Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach |
| 3E03305 | Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach |
| 3E0330M | Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach |
| 3E0330P | Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach |
| 3E03316 | Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Percutaneous |
| 3E03317 | Introduction of Other Thrombolytic into Peripheral Vein, Percutaneous Approach |
| 3E03328 | Introduction of Oxazolidinones into Peripheral Vein, Percutaneous Approach |
| 3E03329 | Introduction of Other Anti-infective into Peripheral Vein, Percutaneous Approach |
| 3E0333Z | Introduction of Anti-inflammatory into Peripheral Vein, Percutaneous Approach |
| 3E0334Z | Introduction of Serum, Toxoid and Vaccine into Peripheral Vein, Percutaneous Approach |
| 3E0336Z | Introduction of Nutritional Substance into Peripheral Vein, Percutaneous Approach |
| 3E0337Z | Introduction of Electrolytic and Water Balance Substance into Peripheral Vein, Percutaneous Approach |
| 3E033FZ | Introduction of Intracirculatory Anesthetic into Peripheral Vein, Percutaneous Approach |
| 3E033GC | Introduction of Other Therapeutic Substance into Peripheral Vein, Percutaneous Approach |
| 3E033GN | Introduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Percutaneous Approach |
| 3E033GQ | Introduction of Glucarpidase into Peripheral Vein, Percutaneous Approach |
| 3E033GR | Introduction of Other Therapeutic Monoclonal Antibody into Peripheral Vein, Percutaneous Approach |
| 3E033HZ | Introduction of Radioactive Substance into Peripheral Vein, Percutaneous Approach |
| 3E033KZ | Introduction of Other Diagnostic Substance into Peripheral Vein, Percutaneous Approach |
| 3E033NZ | Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Percutaneous Approach |
| 3E033PZ | Introduction of Platelet Inhibitor into Peripheral Vein, Percutaneous Approach |
| 3E033RZ | Introduction of Antiarrhythmic into Peripheral Vein, Percutaneous Approach |
| 3E033TZ | Introduction of Destructive Agent into Peripheral Vein, Percutaneous Approach |
| 3E033U0 | Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach |
| 3E033U1 | Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach |
| 3E033VG | Introduction of Insulin into Peripheral Vein, Percutaneous Approach |
| 3E033VH | Introduction of Human B-type Natriuretic Peptide into Peripheral Vein, Percutaneous Approach |
| 3E033VJ | Introduction of Other Hormone into Peripheral Vein, Percutaneous Approach |
| 3E033WK | Introduction of Immunostimulator into Peripheral Vein, Percutaneous |
| 3E033WL | Introduction of Immunosuppressive into Peripheral Vein, Percutaneous |
| 3E033XZ | Introduction of Vasopressor into Peripheral Vein, Percutaneous Approach |
